ICUCW · SeaStar Medical Holding Corp
Substantial doubt about the company's ability to continue as a going concern.
“The Company believes that these conditions raise substantial doubt about its ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Price & Indicators
The closing range uses available history since Jul 24, 2026; less than a full year is stored.
Up next
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 12, 2026TL;DR. SeaStar Medical reported Q2 2026 QUELIMMUNE net revenue of $615,000, up 82% year-over-year, with the customer base expanding to 20 top children's hospitals toward a year-end goal of 25, while the NEUTRALIZE-AKI pivotal trial advanced to 223 of 339 enrolled patients with enrollment expected around year-end or Q1 2027.
- + QUELIMMUNE net revenue grew 82% year-over-year to $615,000 in Q2 2026
- + Pediatric customer base doubled to 20 of the top 50 children's hospitals, tracking to the 2026 goal of 25
- + NEUTRALIZE-AKI pivotal trial enrollment advanced to 223 of 339 patients with additional sites activated
- + CMS assigned dedicated ICD-10-PCS codes for SCD therapy, effective October 1, 2026, simplifying hospital billing
- − Q2 net loss widened to $3.7 million from $2.0 million a year ago
- − Cash on hand declined to $7.0 million at June 30, 2026 from $12.0 million at year-end 2025
- − Operating expenses more than doubled to $4.4 million in Q2 2026 from $2.1 million a year ago
- − Recent monthly enrollment of 8-12 patients is below the company's preferred pace, with trial completion pushed to year-end or Q1 2027
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders illustrative — not investment adviceIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Gross margin | 91% | second quarter 2026 | — |
| NEUTRALIZE-AKI trial enrollment target | 339 | second quarter 2026 | — |
| NEUTRALIZE-AKI trial patients enrolled | 223 | second quarter 2026 | — |
| QUELIMMUNE customer base | 20 | second quarter 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ICUCW
this stock
SeaStar Medical Holding Corp
|
$10.62M | — | +814.1% | — | — |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.00B | +14.1% | +46.2% | 29.9 | 1.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.88B | +4.6% | +20.8% | 19.9 | 2.1% |
|
MRNA
Moderna, Inc.
|
$79.89B | +574.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.42B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- % held
- 30.0%
- Reported
- 2 of 33
- Top holder
- BOOTHBAY FUND MANAGEMENT,…
- Filed
- Oct 5, 2026
- This year
- 17
SeaStar Medical Holding Corporation completed an offering on October 5, 2026, raising approximately $3.3 million gross from warrant exercises at $3.866 per share, and issuing new Series A and Series B warrants for 854,002 shares each at $3.616 per share.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ICUCW | -22.5% | -4.3% | — | -4.9% | — |
| SPY | -0.1% | 0.0% | +5.8% | +0.4% | +12.2% |
| vs SPY | -22.4% | -4.3% | — | -5.3% | — |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.